PPP1R3D: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: PPP1R3D

NCBI ID: G5509

PPP1R3D

PPP1R3D: A Promising Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 10% of the global population experiences chronic pain, with approximately 50% of individuals experiencing persistent pain. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuroinflammatory diseases, and systemic illnesses. While several medications have been developed to alleviate chronic pain, the lack of effective new treatments remains a significant challenge in managing this debilitating condition.

PPP1R3D: A Potential Drug Target and Biomarker

The protein phosphatase 1 (PPP1R3D) is a key regulator of spinal pain modulation, which has been implicated in the development and maintenance of chronic pain. PPP1R3D is a protein that is expressed in various tissues, including spinal cord neurons, and has been shown to play a crucial role in the regulation of pain perception and spinal cord function.

Recent studies have suggested that PPP1R3D may be a promising drug target for the treatment of chronic pain. By inhibiting the activity of PPP1R3D, researchers have found that they can effectively reduce pain in experimental models of spinal pain. Additionally, preclinical studies have suggested that PPP1R3D may be a biomarker for evaluating the efficacy of potential pain treatments.

The Potential Mechanisms of PPP1R3D as a Drug Target

Several mechanisms have been proposed to explain the role of PPP1R3D in pain modulation. One of the main mechanisms is the regulation of pain perception by modulating the activity of pain-sensitive neurons. PPP1R3D has been shown to play a role in the regulation of neurotransmitter release from pain-sensitive neurons, which may contribute to the development of chronic pain.

Another potential mechanism of PPP1R3D's role in pain modulation is the regulation of spinal cord function. PPP1R3D has been shown to play a role in the regulation of spinal cord neurotransmitter release and in the modulation of spinal cord electrical activity. These functions may be important for the development and maintenance of chronic pain.

The Potential Use of PPP1R3D as a Biomarker

PPP1R3D has also been suggested as a potential biomarker for the evaluation of the efficacy of potential pain treatments. By measuring the activity of PPP1R3D, researchers can determine whether the treatment is effective in reducing pain. This may be a useful tool in the development of new pain treatments, as it can provide valuable information about the drug's effectiveness.

Conclusion

PPP1R3D is a protein that has been shown to play a crucial role in the regulation of pain modulation. The potential use of PPP1R3D as a drug target and biomarker makes it an attractive candidate for the development of new treatments for chronic pain. Further research is needed to fully understand the role of PPP1R3D in pain modulation and its potential as a drug target and biomarker.

Protein Name: Protein Phosphatase 1 Regulatory Subunit 3D

Functions: Seems to act as a glycogen-targeting subunit for PP1. PP1 is essential for cell division, and participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis

The "PPP1R3D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R3D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets